Medtronic unveils new study results for its CoreValve system, which shows 1-year survival rates above 80% and improved quality of life for patients at 1 and 6 months.

TCT 2012 logo

Minneapolis health giant Medtronic (NYSE:MDT) unveiled new findings from its CoreValve Advance study, showing a 1-year survival rate of 82.1% and improved health-rated quality of life at 1 and 6 months.

Medtronic's CoreValve device is a self-expanding heart valve prosthetic that can be delivered via catheter rather than through surgery.

The Advance study included 996 patients across 44 TAVI centers in 12 countries, finding quality of life improvements among even the highest-risk patients, according to the company.